clinical trial

[Science] An unusual receptor binding domain (RBD)-RBD interaction in the ACE2-spike complex supported the open conformation and further reinforced ACE2 binding to the spike trimer.

[Celltrion Group] Celltrion Group announced it has submitted an IND application to conduct a global Phase III clinical trial evaluating the efficacy and safety of an inhaled COVID-19 antibody cocktail therapy for patients with mild-to-moderate symptoms of COVID-19.

[uniQure N.V.] uniQure N.V. announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.

[CRISPR Therapeutics] CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of type I diabetes.

[BioRestorative Therapies, Inc. (Globe Newswire, Inc.)] BioRestorative Therapies, Inc. announced that it has initiated the site selection process for its active Phase II clinical trial targeting chronic lumbar disc disease with BRTX-100, a product formulated from autologous cultured MSCs collected from the patient’s bone marrow.

[Seagen, Inc.] Seagen, Inc. announced that the Phase III ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival in patients with advanced classical Hodgkin lymphoma following treatment with ADCETRIS in combination with chemotherapy.